CVRx, Inc.

AI-generated fair value estimate for this company.

Method: 10-year revenue-and-margin-ramp DCF: $61.19M TTM revenue (+12% YoY) growing 8%/year; FCF margin ramping from -20% today to +15% by year 10 as Barostim adoption scales and the company resolves recent sales-execution issues; 13% discount rate (elevated for execution risk); 3% terminal growth; plus $5.20M net cash. Equity value $55.45M / 26.64M shares = $2.08/share.

Reasoning: CVRx's stock has fallen ~80% on sales-execution and leadership issues despite continued double-digit revenue growth for its FDA-approved Barostim neuromodulation device, and a shareholder has publicly called for a strategic sale review; a margin-ramp DCF reflecting a path back to profitability (rather than extrapolating the current depressed/disrupted cost structure) is the appropriate rigorous method and supports a value modestly above the current distressed share price.